<DOC>
	<DOCNO>NCT03053063</DOCNO>
	<brief_summary>The primary objective study evaluate whether selonsertib ( SEL ; GS-4997 ) cause fibrosis regression reduce associate complication adult cirrhosis due NASH .</brief_summary>
	<brief_title>Safety Efficacy Selonsertib Adults With Compensated Cirrhosis Due Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Liver biopsy consistent NASH cirrhosis ( F4 fibrosis ) accord NASH Clinical Research Network ( CRN ) classification , opinion central reader Has follow laboratory parameter screen visit , determined central laboratory : Alanine aminotransferase ( ALT ) ≤ 8 x upper limit normal ( ULN ) Creatinine Clearance ( CLcr ) ≥ 30 milliliter/minute ( mL/min ) , calculate CockcroftGault equation HbA1c ≤ 9.5 % Key Prior history decompensated liver disease include ascites , hepatic encephalopathy ( HE ) , variceal bleeding ChildPugh ( CP ) score &gt; 7 , determine screen Model Endstage Liver Disease ( MELD ) score &gt; 12 , determine screen Other cause liver disease include , limited , alcoholic liver disease , hepatitis B , hepatitis C , autoimmune disorder , druginduced hepatotoxicity , Wilson disease , iron overload , alpha1antitryspin deficiency , base medical history centralize review liver histology . History liver transplantation Current history hepatocellular carcinoma ( HCC ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>